Compare SMX Security Matters plc (SMX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SMX Security Matters plc vs Sanofi SA — how do they compare? SMX Security Matters plc trades at $3.84 (market cap $4.13M), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 23046× SMX Security Matters plc's market cap, and Sanofi SA pays a 6.01% dividend while SMX Security Matters plc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SMX Security Matters plc for 21 Days and Sanofi SA for 94 Days on average.
| SMX | SNY | |
|---|---|---|
Market Cap | $4.13M | $95.18B |
Volume | 124,362 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $74.08K | $52.34 |
52-Week Low | $3.79 | $39.51 |
Typical Hold Time | 21 Days | 94 Days |
Enterprise Value | -$27.20M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMX trades at $3.80, down 2.56% with a bearish technical outlook despite oversold RSI readings. The company shows severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22%. Recent news highlights SMX's digital material passport technology gaining media attention from Forbes, TIME, and Boston Herald in September-October 2026, focusing on recycled plastic verification and circular economy applications.
The stock faces substantial fundamental challenges with no current revenue generation and significant operating losses. While media coverage suggests technological potential in material verification, the absence of revenue and massive negative profitability metrics present extreme risk. Investment viability depends entirely on SMX's ability to monetize its technology platform amid ongoing cash burn.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
